FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
0
0
0 Bekeken·
09/21/23
Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.
Laat meer zien
0 Comments
sort Sorteer op